Abstract
Purpose: Casirivimab/imdevimab (REGN-COV), a cocktail of neutralizing antibodies against the receptor-binding domain of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein, was shown to be an effective treatment and post-exposure prophylaxis measure for coronavirus disease 2019 (COVID-19). We assessed the antibody titers among patients who received REGN-COV with the purpose of evaluating this therapeutic and prophylactic option from the serological point of view.
Methods: We collected serological data of patients with COVID-19 who were treated with REGN-COV 1200 mg (casirivimab 600 mg/imdevimab 600 mg). Antibody titers were assessed within 24 h before and within 48 h after the administration of REGN-COV using ARCHITECT SARS-CoV-2 immunoglobulin (Ig)G (IgG NC ), which is against nucleocapsid protein, and ARCHITECT SARS-CoV-2 IgG II Quant (IgG SP ), which is against spike protein.
Results: A total of nine patients were evaluated. IgG SP was elevated after REGN-COV administration with a median of 208,370 Arbitrary Units/mL while simultaneous IgG NC remained low. With the simple linear regression model, the IgG SP after the REGN-COV administration was correlated with the reciprocal of ideal body weight.
Conclusion: The high titer of IgG SP supports the clinical benefit of therapeutic and prophylactic use of REGN-COV from the serological point of view.
Keywords: Antibody titer; COVID-19; Casirivimab/imdevimab; REGN-COV; SARS-CoV-2.
【저자키워드】 COVID-19, SARS-CoV-2., Antibody titer, casirivimab/imdevimab, REGN-COV, 【초록키워드】 Treatment, coronavirus disease, neutralizing antibody, SARS-CoV-2, IgG, Coronavirus disease 2019, coronavirus, Neutralizing antibodies, body weight, Prophylactic, severe acute respiratory syndrome Coronavirus, Spike protein, nucleocapsid protein, Prophylaxis, Receptor-binding domain, Immunoglobulin, Casirivimab, Imdevimab, therapeutic, Patient, Antibody titer, respiratory, serological, SARS-CoV-2 IgG, Antibody titers, cocktail, administration, Support, acute respiratory syndrome, simple linear regression, acute respiratory syndrome coronavirus, acute respiratory syndrome coronavirus 2, serological data, clinical benefit, Architect, Linear regression model, effective, shown, collected, remained, evaluated, elevated, nine, median, treated, correlated, the receptor-binding domain, patients with COVID-19, were assessed, 【제목키워드】 neutralizing antibody, therapy, antibody, Patient, receiving, the SARS-CoV-2,